Cargando…

2410. Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital

BACKGROUND: Clostridioides difficile is an anaerobic spore-forming, toxin-producing Gram-positive bacillus listed by the CDC as an “urgent threat” pathogen. Epidemiologic studies using whole-genome sequencing (WGS) have found that genetically distinct lineages infections occur in hospitalized patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Begum, Khurshida, Alam, M Jahangir, McPherson, Jacob, Costa, Gabriela, Miranda, Julie M, Lancaster, Chris, Garey, Kevin W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810368/ http://dx.doi.org/10.1093/ofid/ofz360.2088

Ejemplares similares

PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255
por: Gonzales-Luna, Anne J., et al.
Publicado: (2020)

510. First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals
por: Alam, M Jahangir, et al.
Publicado: (2018)

1720. Isolation and Characterization of Candida auris From an Active Surveillance System in Texas
por: Alam, M Jahangir, et al.
Publicado: (2019)

2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection
por: Dotson, Kierra M, et al.
Publicado: (2019)

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection
por: McPherson, Jacob, et al.
Publicado: (2022)

First Environmental Investigation of Toxigenic Clostridium difficile at a Large Hospital in Bangladesh
por: Alam, M Jahangir, et al.
Publicado: (2017)

741. Antifungal Resistant Candida glabrata Are Most Commonly Colonized in Clostridioides difficile Infection (CDI) Patient Guts in Texas
por: Begum, Khurshida, et al.
Publicado: (2020)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains
por: Endres, Bradley T, et al.
Publicado: (2019)

2402. Clinical Outcomes Associated with an Emerging Clostridioides difficile Ribotype 255 in Texas
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020)

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

1197. Inhibitory Effect of Ursodeoxycholic Acid on Clostridioides difficile Growth
por: Alnezary, Faris, et al.
Publicado: (2020)

784. A Novel Method to Assess Virulence of Clostridioides difficile: Focus on C. difficile Ribotype 106
por: Almutairi, Masaad, et al.
Publicado: (2020)

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial( )
por: Garey, Kevin W, et al.
Publicado: (2022)

2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes
por: Carlson, Travis J, et al.
Publicado: (2019)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection
por: Garey, Kevin W, et al.
Publicado: (2021)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
por: Mason, Clive, et al.
Publicado: (2021)

2063. Elucidating the Gram-Positive Selective Spectrum Activity of Ibezapolstat; Secondary Analysis from the phase 2a trial
por: Lancaster, Chris, et al.
Publicado: (2023)

Comparison of Risk Stratification Approaches to Identify Patients with Clostridioides difficile Infection at Risk for Multidrug-Resistant Organism Gut Microbiota Colonization
por: Zasowski, Evan J., et al.
Publicado: (2023)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

521. Investigating the Gram-Positive Selective Spectrum of Ibezapolstat, a First-in-Class DNA Polymerase IIIC (Pol IIIC) Inhibitor
por: Jahangir Alam, M, et al.
Publicado: (2022)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

840. Clinical Failure Rates Associated with Hemin-induced Metronidazole Resistance in Clostridioides difficile
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

92180 Prevalence of Clostridioides difficile strains found in Texas soil
por: Zeidan, Amina R., et al.
Publicado: (2021)

277. A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
por: Jo, Jinhee, et al.
Publicado: (2023)

Community Environmental Contamination of Toxigenic Clostridium difficile
por: Alam, M Jahangir, et al.
Publicado: (2017)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor
por: Garey, Kevin W, et al.
Publicado: (2019)

beta* leveling with telescopic ATS squeeze (MD 2410)
por: Wenninger, Jorg, et al.
Publicado: (2017)

2235. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients
por: Olvera, Adilene, et al.
Publicado: (2019)

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence
por: Garey, Kevin W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rge6dpgrmno1n863n91rctqftq